Abstract
The management of pancreatic ductal adenocarcinoma (PDAC) has evolved over the last two decades. Surgical resection remain the only potential cure for this cancer. Therefore, there is an emerging emphasis on neoadjuvant therapy to maximize the probability of resection, and identify failures early. The benefit of FOLFIRINOX in various clinical stages of PDAC have been practice changing. The addition of nab-paclitaxel to the traditional gemcitabine regimen added another option for treatment. In addition, immunotherapy and targeted therapies are applicable, based on molecular features and germline alterations; albeit, these are applicable to only a small minority of patients. In this review article, we discuss the key extant literature relevant to various stages of pancreatic cancer. We also summarize ongoing clinical trials which may guide future treatments.
© 2022 by American Society of Clinical OncologyConception and design: All authors
Collection and assembly of data: All authors
Data analysis and interpretation: Davendra P.S. Sohal
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Pancreatic Adenocarcinoma Management
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Yan Jiang
Stock and Other Ownership Interests: Pfizer, Moderna Therapeutics
Davendra P.S. Sohal
Honoraria: Foundation Medicine
Consulting or Advisory Role: Ability Pharma, AstraZeneca/MedImmune, Torus
Speakers' Bureau: Incyte, Genentech
Research Funding: Celgene (Inst), Genentech (Inst), Bristol Myers Squibb (Inst), Incyte (Inst), Rafael Pharmaceuticals (Inst), Apexigen (Inst), Amgen (Inst), Ability Pharma (Inst), AstraZeneca/MedImmune (Inst), FibroGen (Inst), Merck (Inst)
No other potential conflicts of interest were reported.
留言 (0)